Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Breo Ellipta is a prescription inhaled medicine containing fluticasone furoate, a corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist. It is approved for maintenance treatment of chronic obstructive pulmonary disease and for maintenance treatment of asthma in patients age 5 and older. It is taken once daily through the Ellipta dry powder inhaler.
read more about breo ellipta ...Fluticasone furoate acts through glucocorticoid receptors and reduces inflammatory activity in the airways. Vilanterol stimulates beta2-adrenergic receptors on airway smooth muscle, increasing cyclic AMP and relaxing bronchial muscle. The combination pairs an inhaled corticosteroid with long-acting bronchodilation for ongoing asthma or chronic obstructive pulmonary disease treatment.
Breo Ellipta is approved for maintenance treatment of chronic obstructive pulmonary disease and for maintenance treatment of asthma in patients age 5 and older. It is not used for rapid relief of acute bronchospasm. Sudden breathing symptoms require an inhaled short-acting beta2 agonist prescribed for rescue treatment.
Adults with chronic obstructive pulmonary disease use one inhalation of 100 mcg fluticasone furoate with 25 mcg vilanterol once daily. Adults with asthma use 100 with 25 mcg or 200 with 25 mcg once daily. Patients age 12 to 17 use 100 with 25 mcg, while ages 5 to 11 use 50 with 25 mcg once daily.
Breo Ellipta can cause oral candidiasis, pneumonia in patients with chronic obstructive pulmonary disease, adrenal effects, reduced bone mineral density, glaucoma, cataracts, paradoxical bronchospasm, and cardiovascular effects. Patients rinse the mouth with water without swallowing after inhalation to reduce oral candidiasis risk. The inhaler is not used for acute breathing attacks.
Breo Ellipta contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist.
Breo Ellipta is inhaled once daily. The prescribed strength depends on age and whether treatment is for asthma or chronic obstructive pulmonary disease.
No. Breo Ellipta is maintenance treatment and is not indicated for rapid relief of acute bronchospasm.
Rinsing with water after each dose reduces the risk of oral candidiasis linked to the inhaled corticosteroid.
BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder) Prescribing Information. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Breo_Ellipta/pdf/BREO-ELLIPTA-PI-PIL-IFU.PDF. Date Accessed September 16, 2026.
DailyMed - BREO ELLIPTA (fluticasone furoate and vilanterol trifenatate) powder. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96428df1-ea05-431a-98d3-1ec2c4b63878. Date Accessed September 16, 2026.
Fluticasone and Vilanterol Oral Inhalation. MedlinePlus. https://medlineplus.gov/druginfo/meds/a613037.html. Date Accessed September 16, 2026.
GSK Products - BREO ELLIPTA. GSKPro. https://gskpro.com/en-us/products/. Date Accessed September 16, 2026.
Summary of Pharmacology - Fluticasone Furoate/Vilanterol (Breo Ellipta). NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK409764/. Date Accessed September 16, 2026.